Novavax shares enter Warp Speed with cash injection
The biotech has been singled out for a $1.6bn payment for US Covid-19 vaccine development.
Covid-19 takes a toll on medtech’s first quarter
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Big Pharma remains bullish in the face of Covid-19
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.
The crucial trials Medtronic has had to pause
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
Covid-19 adds a new danger to drug launches
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
New Covid-19 test and a decent first quarter buoy Abbott
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
Big Pharma throws out old models in the race to a Covid-19 vaccine
From research collaborations to changes to drug development, pharma will have to find new ways of working to discover Covid-19 treatments.
For Lundbeck’s acquisition strategy bad luck comes in threes
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
A Covid-19 treatment plan slowly emerges
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.
